

## PRESS RELEASE

### Sustainably produced food ingredients

### **BRAIN AG and Roquette successfully complete research collaboration**

- **BRAIN provided solutions for sustainable food ingredient production process**
- **BRAIN and Roquette also partner in DOLCE program for next generation natural sweetening solutions for food**

Zwingenberg (Germany) &  
Lestrem (France)  
21 June 2017

Bioeconomy pioneer BRAIN AG and Roquette, leader in specialty food ingredients and pharmaceutical excipients, have completed a strategic research collaboration which started in 2014. The overall goal was to improve efficiency and sustainability of food ingredient production processes by saving energy, resources and production times.

Within this collaboration BRAIN has identified, developed and optimized biological resources for such sustainable production processes. The R&D work was partly based on BRAIN's huge BioArchive containing more than 53,000 comprehensively characterized, cultivable microorganisms as well as a variety of new enzymes and metabolic pathways.

Dr Guido Meurer, Executive Vice President Producer Strain Development at BRAIN AG, said: "The collaboration with Roquette is a success story, we are very proud of. We are looking forward to a successful expansion of further joined strategic programs."

For BRAIN AG the now completed research collaboration for sustainable food ingredient production processes is business relevant for the segment BioScience, which mainly comprises exclusive R&D-collaborations with

#### Contact:

**B·R·A·I·N**  
Thomas Deichmann  
Head of Public Relations  
Darmstädter Str. 34-36  
64673 Zwingenberg, Germany

Tel.: +49-(0)-6251-9331-72  
td@brain-biotech.de  
www.brain-biotech.de



industry partners. Both parties have agreed to not disclose any more details.

In recent months, the two companies have initiated new collaboration projects. In August 2016, BRAIN AG, Roquette and AnalytiCon Discovery GmbH started the DOLCE program for the development of next generation natural sweetening solutions. In November 2016 two major food categories joined the DOLCE program.

Further information

[Two major food categories have joined DOLCE](#)

[Strategic partnership for the development of next generation natural sweeteners](#)

## About BRAIN

B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN DE0005203947 / WKN 520394) is one of Europe's leading technology companies in the field of industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN identifies previously untapped, efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by help of this „Toolbox of Nature“ are successfully applied in the chemistry, the cosmetics and the food industries. BRAIN's business model is based on two pillars – BioScience and BioIndustrial. The BioScience comprises its frequently exclusive collaboration business with industrial partners. BioIndustrial comprises the development and commercialization of BRAIN's own products and active product components. [www.brain-biotech.de/en](http://www.brain-biotech.de/en).

## Disclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG and are based on information currently available to the management. Forward-looking statements are not guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at BRAIN AG and the BRAIN Group. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking statements.